Le médicament du mois : Edoxaban (Lixiana (R)): nouvel anticoagulant oral pour le traitement et la prévention secondaire des maladies thromboemboliques
SCHEEN, André ; Centre Hospitalier Universitaire de Liège - CHU > Service de diabétologie, nutrition, maladies métaboliques
LANCELLOTTI, Patrizio ; Centre Hospitalier Universitaire de Liège - CHU > Service de cardiologie
Language :
French
Title :
Le médicament du mois : Edoxaban (Lixiana (R)): nouvel anticoagulant oral pour le traitement et la prévention secondaire des maladies thromboemboliques
Alternative titles :
[en] Edoxaban (LIXIANA®): New oral anticoagulant for the treatment and secondary prevention of thromboembolic disease
Publication date :
November 2016
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Peters P, Defraigne JO, Gothot A. - Anticoagulants oraux: nouveaux horizons. Rev Med Liege, 2012, 67, 37-44.
Scheen AJ. - Rivaroxaban (Xarelto®): nouvel anticoagulant oral, inhibiteur direct sélectif du facteur Xa. Rev Med Liege, 2009, 64, 538-543.
Lancellotti P, Scheen AJ. - Dabigatran étexilate (Pradaxa®): anticoagulant oral, inhibiteur direct sélectif de la thrombine. Rev Med Liege, 2010, 65, 588-592.
Melissopoulou M, Ancion A, Lancellotti P, et al. - Recommandations européennes concernant la prise en charge de l'embolie pulmonaire. Rev Med Liege, 2014, 69, 594-599.
Melon P, Lancellotti P. - Recommandations Européennes 2010 pour le traitement anti-thrombotique de la fibrillation auriculaire: nouveaux scores pour l'évaluation des risques d'accident vasculaire cérébral et de saignement. Rev Med Liege, 2010, 65, 580-582.
Kulbertus H, Lancellotti P. - La fibrillation auriculaire: une épidémie du troisième âge ? Rev Med Liege, 2014, 69, 301-308.
Heidbuchel H, Verhamme P, Alings M, et al. - Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J, 2016, Jun. 9. pii: ehw058. [Epub ahead of print].
Greig SL, Garnock-Jones KP. - Apixaban: a review in venous thromboembolism. Drugs, 2016, 76, 1493-1504.
Bounameaux H, Camm AJ. - Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs, 2014, 74, 1209-1231.
Hokusai-VTE Investigators, Büller HR, Décousus H, et al. - Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med, 2013, 369, 1406-1415.
Sprynger M. - L'étude clinique du mois. Hokusai-VTE: edoxaban versus warfarine dans le traitement de la maladie thromboembolique veineuse symptomatique. Rev Med Liege, 2013, 68, 548-551.
Verhamme P, Wells PS, Segers A, et al. - Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind Hokusai-VTE trial. Thromb Haemost, 2016, 116, 747-753.
Shirley M, Dhillon S. - Edoxaban: a review in deep vein thrombosis and pulmonary embolism. Drugs, 2015, 75, 2025-2034.
Giugliano RP, Ruff CT, Braunwald E, et al. - Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2013, 369, 2093-2104.
Ruff CT, Giugliano RP, Braunwald E, et al. - Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet, 2015, 385, 2288-2295.
Mega JL, Walker JR, Ruff CT, et al. - Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet, 2015, 385, 2280-2287.
Kato ET, Giugliano RP, Ruff CT, et al. - Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc, 2016, 5, pii: e003432.
Bohula EA, Giugliano RP, Ruff CT, et al. - Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation, 2016, 134, 24-36.
Magnani G, Giugliano RP, Ruff CT, et al. - Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail, 2016, 18, 1153-1161.
Rost NS, Giugliano RP, Ruff CT, et al. - Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (Effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48). Stroke, 2016, 47, 2075-2082.
Steffel J, Giugliano RP, Braunwald E, et al. - Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis. J Am Coll Cardiol, 2016, 68, 1169-1178.
Giugliano RP, Ruff CT, Rost NS, et al. - Cerebrovascular events in 21105 patients with atrial fibrillation randomized to edoxaban versus warfarin: effective anticoagulation with Factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48. Stroke, 2014, 45, 2372-2378.
Giugliano RP, Ruff CT, Wiviott SD, et al. - Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: insights from the ENGAGE AF-TIMI 48 trial. Am J Med, 2016, 129, 850-857 e852.
Goette A, Merino JL, Ezekowitz MD, et al. - Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet, 2016, 388, 1995-2003.
Yogaratnam D, Ditch K, Medeiros K, et al. - Idarucizumab for reversal of dabigatran-associated anticoagulation. Ann Pharmacother, 2016, 50, 847-854.
